Vaxon Biotech
This article was originally published in Start Up
Executive Summary
Vaxon Biotech is developing therapeutic vaccines that stimulate the immune system to attack cancer cells without harming normal tissue, for a range of indications including prostate, lung, breast, hepatocellular, pancreatic and colon cancer. Based near Paris, Vaxon says it is the first company to develop therapeutic vaccines to treat existing cancers using optimized cryptic peptides, which appear to escape tolerance mechanisms, suggesting their potential in cancer immunotherapy.